Loading clinical trials...

Exercise and Nutrition Interventions for Platinum Chemotherapy-induced Neuropathy R21 | Clinical Trials | Clareo Health

TERMINATEDPHASE2

Exercise and Nutrition Interventions for Platinum Chemotherapy-induced Neuropathy R21

The Effects of Exercise and Nutrition Interventions on Platinum Chemotherapy-induced Peripheral Neuropathy and Interoceptive Brain Circuitry (R21)

NCT05452902•University of Maryland, Baltimore

View on ClinicalTrials.gov

Summary

Chemotherapy-induced peripheral neuropathy (CIPN) is a highly prevalent and severe side-effect of platinum-based chemotherapy, often used to treat gastrointestinal cancers. Unfortunately there are very limited treatments for CIPN. This is a phase II randomized controlled trial to test the preliminary efficacy of exercise vs. nutrition education on CIPN, to systematically investigate the potential roles of inflammation and interoception, and to obtain data with a more accurate effect size to inform a future study.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Have a diagnosis of cancer
•2. Be scheduled to receive platinum chemotherapy (specifically oxaliplatin or cisplatin) without other neurotoxic chemotherapy (taxanes, bortezomib, thalidomide). Patients may be enrolled before their first (preferred), second, or third infusion of neurotoxic chemotherapy
•3. Be able to read English
•4. Be ≥18 years

Exclusion Criteria

•1. Be performing regular exercise, which is any planned physical activity (e.g., brisk walking, aerobics, jogging, bicycling, swimming, rowing, weight lifting, resistance training, yoga, pilates, etc.) performed to increase physical fitness. To be considered exercise, physical activity should be performed 3-5 times per week for 20-60 minutes per session and should be done at a level that increases your breathing rate and causes you to break a sweat.
•2. Have physical limitations (e.g., cardiorespiratory, orthopedic, central nervous system) that contraindicate participation in maximal physiological fitness testing and a low/moderate intensity home-based walking and progressive resistance exercise program.
•3. Have planned surgery or radiation treatment in the 12 weeks after baseline.
•1. Have current or prior cancer in the spine, brainstem, or brain (to allow standard brain MRI analysis)
•2. Have contraindications for MRI scanning (pacemaker, ferrous metal implants, pregnancy, etc. note that most port-a-caths are safe for MRI scanning)

Locations (1)

University of Maryland Medical System

Baltimore, Maryland, United States

Key Dates

Start Date

January 19, 2023

Primary Completion Date

September 25, 2025

Completion Date

September 25, 2025

Last Updated

January 26, 2026

Enrollment

ACTUAL participants

Conditions

Chemotherapy-induced Peripheral Neuropathy

Interventions

EXCAP Exercise

BEHAVIORAL

Nutrition Education

BEHAVIORAL

Use of PEA and Scutellaria in Synergy With Therapeutic Exercise in Chemotherapy-induced Peripheral Neuropathy (CIPN): a Clinical Trial

NCT07352514

Chemotherapy-induced Peripheral Neuropathy (CIPN)Neuropathic Pain

View study

RECRUITINGNA

Cryocompression for CIPN

NCT07064798

Chemotherapy-induced Peripheral NeuropathyTaxane-Induced Peripheral Neuropathy+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 26, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Exercise and Nutrition Interventions for Platinum Chemotherapy-induced Neuropathy R21

Inclusion Criteria

Exclusion Criteria

Use of PEA and Scutellaria in Synergy With Therapeutic Exercise in Chemotherapy-induced Peripheral Neuropathy (CIPN): a Clinical Trial

Cryocompression for CIPN

Compression Stockings to Prevent Peripheral Neuropathy Caused by Antibody-Drug Conjugates in Urothelial Carcinoma Patients

GM1 Prophylaxis for Nab-paclitaxel-associated Chemotherapy-induced Peripheral Neuropathy (CIPN) in Patients With Breast Cancer

International CIPN Assessment and Validation Study

Efficacy and Safety of Duloxetine in Chinese Solid Tumor Patients with Taxanes-induced Painful Peripheral Neuropathy